IMMUNE CHECKPOINT INHIBITORS
Cardiotoxicity Associated With Immune Checkpoint Inhibitors: A Systemic Review and Meta-Analysis
Results from a systematic review and meta-analysis of phase II and III clinical trials reporting cardiotoxicities with monotherapy or the combination of anti–PD-1/PD-L1 and/or anti–CTLA-4 agents suggests that the overall risk of cardiac immune-related adverse events (irAEs) is not significantly higher with immune checkpoint inhibitors compared with placebo or standard of care. Further, the reported severe cardiac irAEs (e.g., myocarditis and cardiac arrest) were very low.
ASCO Annual Meeting 2020 (Abstract)Meet the Faculty
Videos
-
Immune Checkpoint Inhibitors Managing Cardiotoxicity Associated With Immune Checkpoint Inhibitor Therapy
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: Incidence and Patient Risk Factors
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: The Pharmacist Perspective
